![Cytarabine Cytosine Arabinoside, Ara-C Chemotherapy Drug Molecule. Used in Treatment of Acute Myeloid Leukemia AML, Acute. Stock Illustration - Illustration of model, lymphoma: 187975189 Cytarabine Cytosine Arabinoside, Ara-C Chemotherapy Drug Molecule. Used in Treatment of Acute Myeloid Leukemia AML, Acute. Stock Illustration - Illustration of model, lymphoma: 187975189](https://thumbs.dreamstime.com/b/cytarabine-cytosine-arabinoside-ara-c-chemotherapy-drug-molecule-used-treatment-acute-myeloid-leukemia-aml-acute-lymphocytic-187975189.jpg)
Cytarabine Cytosine Arabinoside, Ara-C Chemotherapy Drug Molecule. Used in Treatment of Acute Myeloid Leukemia AML, Acute. Stock Illustration - Illustration of model, lymphoma: 187975189
![Cytarabine (cytosine arabinoside, ara-c) chemotherapy drug molecule. used in treatment of acute myeloid leukemia (aml), acute | CanStock Cytarabine (cytosine arabinoside, ara-c) chemotherapy drug molecule. used in treatment of acute myeloid leukemia (aml), acute | CanStock](https://cdn.w600.comps.canstockphoto.com/cytarabine-cytosine-arabinoside-ara-c-clipart-vector_csp23751853.jpg)
Cytarabine (cytosine arabinoside, ara-c) chemotherapy drug molecule. used in treatment of acute myeloid leukemia (aml), acute | CanStock
![The effects of cytarabine combined with ginsenoside compound K synergistically induce DNA damage in acute myeloid leukemia cells - ScienceDirect The effects of cytarabine combined with ginsenoside compound K synergistically induce DNA damage in acute myeloid leukemia cells - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0753332220310052-ga1.jpg)
The effects of cytarabine combined with ginsenoside compound K synergistically induce DNA damage in acute myeloid leukemia cells - ScienceDirect
![IJMS | Free Full-Text | Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML. A Mini Review | HTML IJMS | Free Full-Text | Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML. A Mini Review | HTML](https://www.mdpi.com/ijms/ijms-22-04955/article_deploy/html/images/ijms-22-04955-g002.png)
IJMS | Free Full-Text | Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML. A Mini Review | HTML
![Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-020-07701-8/MediaObjects/12885_2020_7701_Fig3_HTML.png)
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text
![Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-020-07701-8/MediaObjects/12885_2020_7701_Fig6_HTML.png)
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text
![Structural insights into mutagenicity of anticancer nucleoside analog cytarabine during replication by DNA polymerase η | Scientific Reports Structural insights into mutagenicity of anticancer nucleoside analog cytarabine during replication by DNA polymerase η | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-019-52703-7/MediaObjects/41598_2019_52703_Fig1_HTML.png)
Structural insights into mutagenicity of anticancer nucleoside analog cytarabine during replication by DNA polymerase η | Scientific Reports
![Frontiers | ATP Release from Chemotherapy-Treated Dying Leukemia Cells Elicits an Immune Suppressive Effect by Increasing Regulatory T Cells and Tolerogenic Dendritic Cells Frontiers | ATP Release from Chemotherapy-Treated Dying Leukemia Cells Elicits an Immune Suppressive Effect by Increasing Regulatory T Cells and Tolerogenic Dendritic Cells](https://www.frontiersin.org/files/Articles/319887/fimmu-08-01918-HTML-r1/image_m/fimmu-08-01918-g001.jpg)
Frontiers | ATP Release from Chemotherapy-Treated Dying Leukemia Cells Elicits an Immune Suppressive Effect by Increasing Regulatory T Cells and Tolerogenic Dendritic Cells
![Cytarabine Injection, for Clinical, Vial, Rs 900/piece Million Health Pharmaceuticals | ID: 9183727197 Cytarabine Injection, for Clinical, Vial, Rs 900/piece Million Health Pharmaceuticals | ID: 9183727197](https://3.imimg.com/data3/TN/TK/MY-10954059/cytarabine-injection-1000x1000.jpg)
Cytarabine Injection, for Clinical, Vial, Rs 900/piece Million Health Pharmaceuticals | ID: 9183727197
![Cytarabine Cytosine Arabinoside, Ara-C Chemotherapy Drug Molecule. Used in Treatment of Acute Myeloid Leukemia AML, Acute. Stock Vector - Illustration of arabinofuranosyl, cancer: 187174096 Cytarabine Cytosine Arabinoside, Ara-C Chemotherapy Drug Molecule. Used in Treatment of Acute Myeloid Leukemia AML, Acute. Stock Vector - Illustration of arabinofuranosyl, cancer: 187174096](https://thumbs.dreamstime.com/b/cytarabine-cytosine-arabinoside-ara-c-chemotherapy-drug-molecule-used-treatment-acute-myeloid-leukemia-aml-acute-lymphocytic-187174096.jpg)
Cytarabine Cytosine Arabinoside, Ara-C Chemotherapy Drug Molecule. Used in Treatment of Acute Myeloid Leukemia AML, Acute. Stock Vector - Illustration of arabinofuranosyl, cancer: 187174096
![Chemotherapy dosing schedule. The schedule for ARA-C (200 mg/m 2 /d),... | Download Scientific Diagram Chemotherapy dosing schedule. The schedule for ARA-C (200 mg/m 2 /d),... | Download Scientific Diagram](https://www.researchgate.net/profile/Gareth-Gerrard/publication/8451537/figure/fig1/AS:341207357116424@1458361581940/Chemotherapy-dosing-schedule-The-schedule-for-ARA-C-200-mg-m-2-d-daunorubicin-50.png)
Chemotherapy dosing schedule. The schedule for ARA-C (200 mg/m 2 /d),... | Download Scientific Diagram
![A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia | Leukemia A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia | Leukemia](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fleu.2016.225/MediaObjects/41375_2017_Article_BFleu2016225_Fig1_HTML.jpg)
A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia | Leukemia
![Cytarabine (cytosine Arabinoside, Ara-C) Chemotherapy Drug Molecule. Used in Treatment of Acute Myeloid Leukemia (AML), Acute Stock Illustration - Illustration of lymphocytic, lymphoma: 188460947 Cytarabine (cytosine Arabinoside, Ara-C) Chemotherapy Drug Molecule. Used in Treatment of Acute Myeloid Leukemia (AML), Acute Stock Illustration - Illustration of lymphocytic, lymphoma: 188460947](https://thumbs.dreamstime.com/b/cytarabine-cytosine-arabinoside-ara-c-chemotherapy-drug-molecule-used-treatment-acute-myeloid-leukemia-aml-acute-lymphocytic-188460947.jpg)